Fanelli A, Hadjadj S, Gallois Y, Fumeron F, Betoule D, Grandchamp B, Marre M
Laboratoire de nutrition humaine, faculté de médecine Xavier Bichat, 16, rue Henri Huchard, BP 416, 75870 Paris.
Arch Mal Coeur Vaiss. 2002 Jul-Aug;95(7-8):701-8.
Polymorphisms of the -106 mutation and z - 2 or z + 2 microsatellites (-2.1 kb) of the Aldose Reductase (AR) gene have been associated to microangiopathic complications of the diabetes mellitus. The study aimed to establish a relation between the occurrence and progression of the renal and retinal complications and these polymorphisms. The genotypes were realised in 3 populations: DESIR (n = 369), non-diabetic control subjects from the general French population: GENEDIAB (n = 494), type 1 diabetic patients who are suffering from proliferative retinopathy associated with a variable seriousness nephropathy (absent: n = 157; incipient: n = 104; established: n = 126; advanced: n = 107); SURGENE (n = 310), type 1 diabetic patients whom the renal status is prospectively assessed since 1989 in one single center Angers University Hospital. The genotype of the -106 polymorphism was determined using the Molecular Beacons. For the microsatellites analysis, we used an automatized method (GeneScan Abi Prism 3100). There was a strong linkage disequilibrium between the z - 2 allele and the T allele (chi 2 = 120; p = 0.001). The frequency of the C-106T is similar for the DESIR and GENEDIAB cohorts (chi 2 = 3.32; p = 0.19); the Hardy Weinberg law was verified in this group (chi 2 = 0.001, 0.9; p = 1.5 and 0.5 respectively). The law was not verified for the SURGENE cohort (chi 2 = 4.7; p = 0.03) where the frequency of the TT genotype was significantly more important compared to the DESIR population (chi 2 = 6.4; p = 0.01). The z, z - 2 and z + 2 alleles was more frequent compared with other alleles (n = 909, 830 and 349; 39, 38 and 15%). The frequency of the C-106T and microsatellites genotypes did not parallel the nephropathy staging in the GENEDIAB population (chi 2 = 10.9, 2.7, 2.4; p = NS respectively). In the SURGENE population, the survival without renal events did not differ according C-106T and z - 2 or z + 2 microsatellites genotypes (log-rank: 0.6, 3.9, 0.1; p = NS respectively). At the end of the follow-up, we found an effect of the -106 mutation and of the z - 2 microsatellite on the staging of the retinopathy (chi 2 tendency test = 4.61, 0.12; p = 0.031, 0.02; 6 d.f., respectively). The logistic regression multivariable analysis shows that the retinopathy during the final evaluation is independently explained by several factors: diabetes duration (p < 0.0001; OR 21.756; 95% CI: 7.024-67.389), presence of nephropathy (p < 0.0001; OR: 4.086; 95% CI: 2.094-7.973), and genotype TT (p = 0.011; OR: 0.38; 95% CI: 0.18-0.803). In contrast, age of diabetes onset (p = 0.112; OR: 1.556; 95% CI: 0.9-2.692), median HbA1c (p = 0.164; OR: 1.479; 95% CI: 0.85-2.576) and sex (p = 0.156; OR: 1.495; 95% CI: 0.856-2.612) have no independent effect. In conclusion, the association of these AR genetic variants seems absent about the renal risk and slight about the retinal risk associated to the type 1 diabetes mellitus.
醛糖还原酶(AR)基因-106突变及z - 2或z + 2微卫星(-2.1 kb)的多态性与糖尿病微血管并发症相关。本研究旨在确定肾脏和视网膜并发症的发生及进展与这些多态性之间的关系。对3组人群进行了基因分型:DESIR(n = 369),来自法国普通人群的非糖尿病对照者;GENEDIAB(n = 494),患有增殖性视网膜病变且伴有不同严重程度肾病的1型糖尿病患者(无肾病:n = 157;早期肾病:n = 104;确诊肾病:n = 126;晚期肾病:n = 107);SURGENE(n = 310),自1989年起在昂热大学医院单一中心前瞻性评估肾脏状况的1型糖尿病患者。使用分子信标确定-106多态性的基因型。对于微卫星分析,我们采用了自动化方法(GeneScan Abi Prism 3100)。z - 2等位基因与T等位基因之间存在强连锁不平衡(卡方= 120;p = 0.001)。DESIR和GENEDIAB队列中C-106T的频率相似(卡方= 3.32;p = 0.19);该组符合哈迪-温伯格定律(卡方分别为0.001、0.9;p分别为1.5和0.5)。SURGENE队列不符合该定律(卡方= 4.7;p = 0.03),其中TT基因型的频率与DESIR人群相比显著更高(卡方= 6.4;p = 0.01)。z、z - 2和z + 2等位基因比其他等位基因更常见(n = 909、830和349;39%、38%和15%)。GENEDIAB人群中C-106T和微卫星基因型的频率与肾病分期不平行(卡方分别为10.9、2.7、2.4;p均无统计学意义)。在SURGENE人群中,根据C-106T和z - 2或z + 2微卫星基因型,无肾脏事件的生存率无差异(对数秩检验:0.6、3.9、0.1;p均无统计学意义)。随访结束时,我们发现-106突变和z - 2微卫星对视网膜病变分期有影响(卡方趋势检验分别为4.61、0.12;p = 0.031、0.02;自由度为6)。多变量逻辑回归分析表明,最终评估时的视网膜病变可由几个因素独立解释:糖尿病病程(p < 0.0001;比值比21.756;95%置信区间:7.024 - 67.389)、肾病的存在(p < 0.0001;比值比:4.086;95%置信区间:2.094 - 7.973)以及基因型TT(p = 0.011;比值比:0.38;95%置信区间:0.18 - 0.803)。相比之下,糖尿病发病年龄(p = 0.112;比值比:1.556;95%置信区间:0.9 - 2.692)、糖化血红蛋白中位数(p = 0.164;比值比:1.479;95%置信区间:0.85 - 2.576)和性别(p = 0.156;比值比:1.495;95%置信区间:0.856 - 2.612)无独立影响。总之,这些AR基因变异与1型糖尿病相关的肾脏风险似乎无关,与视网膜风险的关联较小。